Dr. Andy Rawstron qualified from Edinburgh University with a BSc in Immunology in 1992. He became a Clinical Scientist at the Haematological Malignancy Diagnostic Service in Leeds and completed a PhD on cellular and molecular aspects of multiple myeloma in 2002. He has co-authored more than 60 publications in the field of myeloma and was a key contributor to the recent Clinical Cytometry special issue on the flow cytometric detection of MRD in myeloma. Andy's work into the understanding of CLL, both in terms of defining the nature of the precursor condition Monoclonal B-Lymphocytosis and in developing and standardizing the assessment of minimal residual disease (MRD) in CLL, has been internationally recognized. His work in coordinating a standard approach to MRD analysis in CLL has encouraged close collaboration between many of the laboratories on the cutting edge of CLL research. Andy has a hospital service commitment to the develop, select and interpret relevant tests for the diagnosis, treatment and monitoring of haematological malignancy. Within this role he has developed an award-winning service for monitoring people with MGUS, CML and CLL before and after treatment which provides regular postal monitoring for over 2,000 people.